Advertisement
Advertisement

PVLA

PVLA logo

Palvella Therapeutics, Inc. Common Stock

155.90
USD
Sponsored
-1.34
-0.85%
Sep 08, 14:51 UTC -4
Open

PVLA Earnings Reports

Positive Surprise Ratio

PVLA beat 22 of 39 last estimates.

56%

Next Report

Date of Next Report
Nov 09, 2026
Estimate for Q3 26 (Revenue/ EPS)
--
/
-$1.77
Implied change from Q2 26 (Revenue/ EPS)
--
/
+16.45%
Implied change from Q3 25 (Revenue/ EPS)
--
/
+71.84%

Palvella Therapeutics, Inc. Common Stock earnings per share and revenue

On Aug 04, 2026, PVLA reported earnings of -1.52 USD per share (EPS) for Q2 26, missing the estimate of -1.18 USD, resulting in a -28.54% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +7.96% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 11 analysts forecast an EPS of -1.77 USD, with revenue projected to reach -- USD, implying an increase of 16.45% EPS, and increase of 0.00% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Clinuvel Pharmaceuticals Limited - ADR
Report Date
Aug 27, 2026 For Q4 26
Estimate
$0.50
Actual
-
Surprise
-
logo
Anavex Life Sciences
Report Date
Aug 25, 2026 For Q3 26
Estimate
-$0.08
Actual
-$0.08
Surprise
+1.96%
logo
Molecular Partners AG - ADR
Report Date
Aug 25, 2026 For Q2 26
Estimate
-
Actual
-$0.35
Surprise
-
FAQ
For Q2 2026, Palvella Therapeutics, Inc. Common Stock reported EPS of -$1.52, missing estimates by -28.54%, and revenue of $0.00, 0% as expectations.
The stock price moved up 7.96%, changed from $140.78 before the earnings release to $151.99 the day after.
The next earning report is scheduled for Nov 09, 2026.
Based on 11 analysts, Palvella Therapeutics, Inc. Common Stock is expected to report EPS of -$1.77 and revenue of -- for Q3 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement